Skip to main content
Figure 2 | Molecular Medicine

Figure 2

From: Interleukin-33 Ameliorates Experimental Colitis through Promoting Th2/Foxp3+ Regulatory T-Cell Responses in Mice

Figure 2

rIL-33 treatment decreases the severity of TNBS-induced colitis. (A–D) Mice with TNBS-induced colitis were treated with PBS, rIL-33, IgG or anti-IL-33 antibody as described in Materials and Methods. (A) The body weight variations of original weight were recorded on d 4 after the TNBS inoculation. (B) The macroscopic score of the colon was assessed. Data indicate the mean ± SD of all experiments. (C, D) The histology of tissue sections from TNBS-treated mice, as indicated in the above treatment, was analyzed. (E–F) Mice with established colitis with rIL-33 or PBS treatment were also subjected to assess the body weight and histological change. Data indicate mean ± SD (n = 6-8/group); *p < 0.05. All data are representative of one of three independent experiments.

Back to article page